[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Stanford University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":634},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,370,0,25,[9,41,63,86,119,151,181,199,225,251,271,296,321,347,366,392,421,444,463,483,507,544,577,596,616],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100651984","characterization-of-skin-changes-clinical-physiological-and-pathological-from-the-use-of-moisturizers-in-participants-with-cancer-experiencing-dermatological-adverse-events-100651984",false,"NCT07767448","Characterization of Skin Changes From the Use of Moisturizers in Participants With Cancer Experiencing Dermatological Adverse Events","Characterization of Skin Changes (Clinical, Physiological and Pathological) Leading to Dermatological Adverse Events From Chemotherapy, Targeted Therapy, Hormonal Therapy, and Immune Checkpoint Inhibitors","Inclusion Criteria:\n\n* Adult patient (18 years or older).\n* Patients diagnosed with cancer.\n* Patient receiving cancer treatment or therapy (receiving chemotherapy, targeted treatment, hormonal therapy, and\u002For immune checkpoint inhibitors).\n* Patient experiencing a dermatological adverse event from a cancer treatment or therapy.\n\nExclusion Criteria:\n\n* Patient is unable to understand scope of the study.\n* Patient is unable to provide written informed consent.\n* Patient is healthy.","ALL","18 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to evaluate whether cosmeceutical topical moisturizers can help with skin dryness in participants with cancer experiencing a dermatological adverse event from cancer therapies. The main question it aims to answer is:\n\nDoes cosmeceutical topical moisturizers help with skin dryness?\n\nParticipants will:\n\n* Visit the clinic for a baseline visit to complete skin evaluation and tests.\n* Apply cosmeceutical topical moisturizers daily from baseline up until the follow-up visit.\n* Visit the clinic for a follow-up visit (approximately 2-4 weeks from baseline) for a repeat skin evaluation and tests.",[27],"Cancer","NOT_YET_RECRUITING","2026-08-19",{"date":31,"type":32},"2026-08-21","ACTUAL",{"date":34,"type":21},"2026-08",{"date":36,"type":21},"2029-02",{"name":38,"class":39},"Stanford University","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":40},"100639800","early-phase-1-a-pilot-study-of-anselamimab-in-patients-with-al-amyloidoma-and-measurable-tissue-involvement-100639800","NCT07615270","A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement","A Pilot Study of CAEL-101\u002FAnselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement","Inclusion Criteria:\n\n1. AL amyloid deposit confirmed by biopsy and IHC or mass spectrometry\n2. Amyloid deposits are measurable by imaging (ultrasound or cross-sectional)\n3. 18 years or older\n4. ECOG performance status 0-3\n5. Adequate bone marrow reserve, hepatic and renal function as demonstrated by:\n\n   1. Absolute neutrophil count ≥ 1.0 × 109\u002FL\n   2. Platelet count ≥ 75 × 109\u002FL\n   3. Hemoglobin ≥ 9 g\u002FdL\n   4. Total bilirubin ≤ 2 times the upper limit of normal (× ULN) unless due to Gilbert's syndrome.\n   5. Aspartate aminotransferase (AST) ≤ 3 × ULN\n   6. Alanine aminotransferase (ALT) ≤ 3 × ULN\n6. No evidence of cardiac, renal or hepatic involvement by amyloidosis\n\n   1. Echocardiogram with mean wall thickness \\\u003C\u002F= 12mm unless other cardiac cause\n   2. 24 hour urine protein \\\u003C500mg AND estimated glomerular filtration rate (eGFR) \\>50mL\u002Fmin\u002F1.73 sqm (Cockcroft-Gault formula)\n   3. Alkaline phosphatase below upper limit of normal and total liver span \\\u003C\u002F=15cm\n7. Participants of childbearing potential agree to use contraception throughout study an\n8. Ability to understand and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n1. Use of other investigational agents within 30 days of screening\n2. Taking doxycycline within 30 days of screening\n3. Current significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders, or psychiatric disorder.\n4. Major surgery within 4 weeks of enrollment\n5. Pregnant\n6. Breast feeding\n7. Participant is eligible and agreeable to standard of care chemotherapy.\n8. Presence of active infection at the time of screening\n9. Participant with a monoclonal protein or isotypic light chain predominance (increased level of the involved light chain and abnormal free light chain ratio (\\\u003C0.26 or \\>1.65)) ☐\n\n   ☐\n10. Participant with known or suspected systemic AL amyloidosis, or suspicion of other organ involvement.\n11. Lymph node involvement\n12. Involvement of amyloidoma in more than one organ.\n13. AL amyloidoma involving other disease locations except those specified in the protocol\n14. Presence of solitary plasmacytoma\n15. Participant with clinically significant lung disorder or disease\n16. Not a candidate for definitive surgical treatment (i.e., complete resection) of amyloidoma.",{"count":49,"type":21},5,[51],"EARLY_PHASE1","This is an exploratory study to assess the binding of CAEL-101\u002Fanselamimab to amyloid in vivo, recruitment of inflammatory cells and reduction of the amyloid mass.",[54],"AL Amyloidosis",[56],"Anselamimab",{"date":31,"type":32},{"date":59,"type":21},"2026-09",{"date":61,"type":21},"2028-07",{"name":38,"class":39},{"id":64,"slug":65,"hasResults":12,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":17,"minAge":18,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":81,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":85,"locationsCount":40},"100638827","comunicar-community-led-family-centered-communication-for-cancer-survivorship-care-100638827","NCT07606443","COMUNICAR: Community-Led Family-Centered Communication for Cancer Survivorship Care","Inclusion Criteria:\n\n1. Childhood cancer survivor previously treated with chemotherapy and\u002For radiation therapy\n2. Currently age 18-25 years\n3. Identifies as Hispanic\u002FLatino\n4. Currently ≥5 years post cancer diagnosis\n5. Fluent in English or Spanish\n6. Receives medical care at Stanford\n7. Lives within Jacob's Heart service area (zip codes within Monterey, Santa Cruz, Santa Clara, San Benito Counties: https:\u002F\u002Fwww.jacobsheart.org\u002Fservice-area)\n8. Ability to understand and the willingness to provide written informed consent.\n\nExclusion Criteria:\n\n1\\. Lack of proficiency in written and spoken English or Spanish",true,"25 Years",{"count":72,"type":21},18,[24],"This study will test a novel intervention to facilitate family-centered communication among Hispanic\u002FLatino (H\u002FL) young adult childhood cancer survivors (YA-CCS), their support persons, and their clinicians through collaboration between the clinic and a community-based organization.",[76],"Childhood Cancer",[78,79,80],"cancer","hispanic","young adult",{"date":31,"type":32},{"date":83,"type":21},"2026-10",{"date":61,"type":21},{"name":38,"class":39},{"id":87,"slug":88,"hasResults":12,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":12,"sex":17,"minAge":93,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":97,"conditions":98,"keywords":103,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":113,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":40},"100607443","virtual-reality-enhanced-behavioral-activation-for-older-adults-with-depression-100607443","NCT07188623","Virtual Reality-Enhanced Behavioral Activation for Older Adults With Depression","VR-Enhanced BA for Older Adults With Major Depressive Disorder","Inclusion Criteria:\n\n* Patient must meet DSM V criteria for MDD\n* Patient must be at least 65 years of age\n* Patient must be English speaking\n* Without cognitive impairment\n\nExclusion Criteria:\n\n* Substance Use Disorders in past year\n* Any psychosis or bipolar I disorder\n* Any seizure in the last 6 months or untreated epilepsy\n* Current nonsuicidal self-injury or parasuicidal behavior\n* Current suicidal urges and intent\n* Changing psychotherapy treatment within three months of study entry\n* Changing psychotropic medication(s) within two months of study entry","65 Years",{"count":95,"type":21},30,[24],"The primary aims of this study are to assess the feasibility, acceptability, and tolerability of using an immersive virtual reality (VR) headset to engage in behavioral activation (BA) for older adults diagnosed with major depressive disorder (MDD). The secondary aim of this study is to explore the efficacy of using VR to enhance BA therapy in a clinical MDD older adult population.",[99,100,101,102],"Depression - Major Depressive Disorder","Older Adults (65 Years and Older)","Behavioral Activation Treatment","Virtual Reality Therapy",[104,105,106,107,108,109,110,111],"Depression","Older adult","major depressive disorder","MDD","behavioral activation","VR","virtual reality","older adults","RECRUITING",{"date":31,"type":32},{"date":115,"type":32},"2025-09-30",{"date":117,"type":21},"2026-12",{"name":38,"class":39},{"id":120,"slug":121,"hasResults":12,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":12,"sex":126,"minAge":18,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":132,"conditions":133,"keywords":137,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":144,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":150},"100476785","phase-2-oxytocin-pharmacokinetics-and-pharmacodynamics-100476785","NCT05488457","Oxytocin Pharmacokinetics and Pharmacodynamics","Pharmacokinetics and Pharmacodynamics of Oxytocin in Cesarean Delivery","Inclusion Criteria\n\n* 18-50 years old\n* intrauterine pregnancy\n* term (\\>39 weeks gestation or 37-39 weeks gestation with fetal or maternal medical indication for delivery) pregnancy\n* non-emergent (scheduled or unscheduled) cesarean delivery\n\nExclusion Criteria:\n\n* allergy or contraindication to oxytocin\n* inability to provide informed consent","FEMALE","50 Years",{"count":129,"type":21},100,[131],"PHASE2","Oxytocin is the first-line drug to promote contraction of the uterus and prevent atony immediately after delivery. Nonetheless, unpredictable uterine atony refractory to oxytocin affects roughly 250,000 parturients annually in the U.S. and rates are increasing. This two-part study will measure the action of oxytocin at cesarean delivery. The first part will measure the pharmacokinetics of a single intravenous (IV) dose of deuterium-labeled oxytocin. The second part will measure the pharmacodynamics of all plasma oxytocin to see how concentrations correspond to the contractile effect on the uterus.\n\nAfter delivery of the fetus, study subjects will receive a bolus of IV deuterated oxytocin followed by an unlabeled oxytocin infusion. Venous blood samples drawn at multiple time points (within 1 hour after delivery) will be analyzed for plasma concentrations of labeled and unlabeled (endogenous + exogenous infused) oxytocin over time. Plasma concentrations will be compared with 0-10 uterine tone scores measuring uterine contraction strength, to describe the concentration-effect relationship.\n\nThe goal of this study is to define both the pharmacokinetics and pharmacodynamics of oxytocin in parturients to help identify the cause(s) of failed first-line oxytocin therapy.",[134,135,136],"Post Partum Hemorrhage","Cesarean Section Complications","Blood Loss",[138,139,140,141,142,143],"Oxytocin","pharmacokinetics and Pharmacodynamics","Uterine Tone","Postpartum","Elective C-Section","Parturients",{"date":31,"type":32},{"date":146,"type":32},"2025-01-01",{"date":148,"type":21},"2027-12-31",{"name":38,"class":39},2,{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":69,"sex":17,"minAge":158,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":163,"conditions":164,"keywords":170,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":177,"completionDateStruct":178,"leadSponsor":180,"locationsCount":40},"100652891","intervention-on-mathematical-problem-solving-skills-100652891","NCT07778706","Intervention on Mathematical Problem-Solving Skills","Interventions in Math Learning Disabilities: Cognitive and Neural Correlates","Inclusion Criteria:\n\n1. Elementary school-aged children starting from first grade (6-12 years old)\n2. IQ: Participants with a Full Scale IQ \\> 70 on the Wechsler Abbreviated Scale of Intelligence (WASI-II)\n3. Identification of Mathematical Learning Disabilities: Scores below the 20th percentile on two or more Wechsler Individual Achievement Test (WIAT-IV) math subtests\n4. Identification of typically developing children: Scores at or above the 50th percentile on two or more WIAT-IV math subtests\n5. Normal or corrected-to-normal vision and no hearing impairments\n6. Inclusion in MRI scan session: Right-handed\n\nExclusion Criteria:\n\n1. History of neurological or psychiatric disorder (i.e., schizophrenia, psychosis, depression, or attention deficit hyperactivity disorder)\n2. History of trauma involving head injury\n3. Consistent psychiatric medications\n4. Exclusion from MRI scan session: No major contraindication for magnetic resonance imaging (MRI) - braces, metal implants, pacemakers, vascular stents, metallic ear tubes, consistent exposure to metal, or claustrophobia)","6 Years","12 Years",{"count":161,"type":21},160,[24],"The purpose of this study is to investigate neurocognitive mechanisms underlying response to intervention aimed at enhancing and remediating weaknesses in arithmetic skills in children, including those with mathematical learning disabilities (MLD).",[165,166,167,168,169],"Math Learning Disability","Learning Disabilities","Learning Disabilities, Child","Dyscalculia","Child Development",[171,172,173,174],"Mathematical Learning Disabilities","Numerical skills in children","Low math abilities","Early Intervention, Educational","2026-08-18",{"date":31,"type":32},{"date":59,"type":21},{"date":179,"type":21},"2031-09",{"name":38,"class":39},{"id":182,"slug":183,"hasResults":12,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":22,"phases":189,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":193,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":40},"100476725","subscapularis-repair-augmentation-for-total-shoulder-arthroplasty-100476725","NCT05487677","Subscapularis Repair Augmentation for Total Shoulder Arthroplasty","Augmentation of Subscapularis Repair in Total Shoulder Arthroplasty","Inclusion Criteria:\n\n* Total Shoulder Arthroplasty\n\nExclusion Criteria:\n\n* Vulnerable population",{"count":129,"type":21},[24],"The primary purpose of this research is to compare the images obtained by ultrasound between a standard repair of the subscapularis tissue and after repair with a Biobrace. The secondary purpose is to determine if there are any clinical differences.",[192],"Shoulder Injuries",{"date":29,"type":32},{"date":195,"type":32},"2023-12-01",{"date":197,"type":21},"2030-12-01",{"name":38,"class":39},{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":22,"phases":209,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":222,"leadSponsor":224,"locationsCount":40},"100643267","empowered-relief-for-caregivers-100643267","NCT07636980","Empowered Relief for Caregivers","Empowered Relief for Caregivers (ER-CY): A Co-Designed Brief Intervention to Support Families of Youth With Chronic Pain","ER-CY","Inclusion Criteria:\n\n* Caregiver of a youth with a chronic pain diagnosis (\\>3 months in duration)\n* English speaking\n\nExclusion Criteria:\n\n* Significant psychosocial complexity based on clinical team assessment (e.g., severe depression\u002Fanxiety, unable to tolerate a group setting)",{"count":208,"type":21},80,[24],"This study is testing a new program called Empowered Relief for Caregivers (ER-CY), designed to support caregivers of children and teens who live with chronic pain. ER-CY is a single two-hour class delivered online. It teaches skills for managing the stress of caring for a child in pain and for responding to a child's pain in helpful ways.\n\nUp to 80 caregivers of youth with chronic pain will take part in one ER-CY class and then complete surveys and a short interview over the following three months. The researchers want to learn two things: whether caregivers are willing and able to take part and find the program helpful and satisfying, and whether the program lowers caregiver distress and improves their child's day-to-day functioning. What is learned will help guide future programs and care for youth with chronic pain and their families.",[212,213,214,215,216,217],"Chronic Pain","Musculoskeletal Pain","Fibromyalgia","Neuropathic Pain","Complex Regional Pain Syndromes (CRPS)","Abdominal Pain (AP)","2026-08-17",{"date":220,"type":32},"2026-08-20",{"date":83,"type":21},{"date":223,"type":21},"2028-09",{"name":38,"class":39},{"id":226,"slug":227,"hasResults":12,"nctId":228,"briefTitle":229,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":12,"sex":17,"minAge":232,"maxAge":233,"enrollmentInfo":234,"targetDuration":4,"studyType":22,"phases":236,"briefSummary":237,"conditions":238,"keywords":240,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":4},"100642977","large-language-model-driven-personalization-of-virtual-reality-interventions-to-improve-pediatric-inpatient-experience-and-reduce-needle-anxiety-100642977","NCT07637617","Evaluating the Acceptability of AI-Personalized Virtual Reality Picture Books for Hospitalized Pediatric Patients","LLM-audiobook","Inclusion Criteria:\n\n* Between age 9-17\n* Current admission in inpatient unit\n* Able to understand and interact with a virtual reality audiobook in English\n\nExclusion Criteria:\n\n* Legal guardian not present to obtain consent\n* Significant cognitive impairment and\u002For developmental delay\n* History of seizures\n* History of severe motion sickness\n* Severe visual or motor impairment limiting picture book participation\n* Child with active infection of the face or hand\n* Acute medical instability\n* Inability to understand English","9 Years","17 Years",{"count":235,"type":21},15,[24],"Hospitalization strips pediatric patients of the environments, objects, and people that shape their daily lives. Hospitalized pediatric patients routinely experience painful procedures, psychological distress, boredom, and a disorienting loss of personal identity. These experiences measurably worsen anxiety, reduce cooperation with care, and diminish the quality of the inpatient experience for both patients and families. Immersive digital interventions, including VR and tablet-based experiences, have emerged as a promising class of tools for addressing these challenges. Prior studies from The Stanford Chariot Program have demonstrated that digitally delivered, patient-centered experiences can meaningfully reduce procedural anxiety and improve engagement in hospitalized children.\n\nYet, an important limitation persists in these technologies - current digital interventions largely remain in one-size-fits-all formats. Every child receives the same content, regardless of who they are, what they love, or what makes them feel at home in the world. This design limits therapeutic relevance, constrains engagement, and represents a missed opportunity to engage children, reduce anxiety, and enhance their quality of life during hospital stays.",[239],"Large Language Model",[241,242,243],"feasibility","acceptability","usability","2026-08-16",{"date":29,"type":32},{"date":247,"type":21},"2026-09-01",{"date":249,"type":21},"2027-08-31",{"name":38,"class":39},{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":12,"sex":17,"minAge":258,"maxAge":233,"enrollmentInfo":259,"targetDuration":4,"studyType":22,"phases":260,"briefSummary":261,"conditions":262,"keywords":264,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":266,"startDateStruct":267,"completionDateStruct":268,"leadSponsor":270,"locationsCount":4},"100637182","feeding-the-flame-one-day-at-a-time-design-and-acceptability-of-a-serious-game-to-support-medication-adherence-and-education-for-pediatric-solid-organ-transplant-patients-100637182","NCT07609303","Feeding the Flame, One Day at a Time: Design and Acceptability of a Serious Game to Support Medication Adherence and Education for Pediatric Solid Organ Transplant Patients","Mystic Wizard","Inclusion Criteria:\n\n* Between age 7-17\n* History of solid organ transplantation\n* Current admission in inpatient unit\n* Able to understand and interact with a tablet-based game in English\n\nExclusion Criteria:\n\n* Legal guardian not present to obtain consent\n* Child with a significant neurological condition, or major developmental disability\n* Child with active infection of the face or hand\n* History of severe motion sickness\n* Severe visual or motor impairment limiting gameplay participation\n* Acute medical instability\n* Major surgery within the last 48 hours\n* Inability to understand English","7 Years",{"count":235,"type":21},[24],"Children and teenagers who receive a solid organ transplant (such as a kidney, liver, or heart) must take medications every day to keep their new organ healthy. Taking these medications correctly and on time is one of the most important parts of staying well after a transplant, but it can be hard for young patients to understand why this matters and to keep up with their routines. Doctors and nurses usually teach patients about their transplant through conversations, which may not always be engaging or easy for kids to remember.\n\nThis study looks at a new way to help young transplant patients learn about their condition and their medications: an educational game played on a tablet. The purpose of the study is to find out what patients think of the game and how well it works for them. Researchers want to know whether young patients find the game acceptable and enjoyable, whether it is easy to use, whether it makes them feel motivated and capable, and how engaged they feel while playing.\n\nTo do this, patients will play the tablet game and then share their experiences. After playing, they will take part in a small group interview where they talk about what they liked, what was confusing, and whether the game helped them understand their transplant and medications. They will also fill out short questionnaires about how easy the game was to use and how engaging it felt.\n\nThe researchers' hypothesis is that pediatric solid organ transplant patients will find the educational tablet-based game acceptable, easy to use, and engaging, and that it will be a welcome and helpful tool for learning about their transplant care. The findings will help guide whether this kind of game could be used to support transplant education for children and teens.",[263],"Solid Organ Transplant",[265],"Education",{"date":175,"type":32},{"date":247,"type":21},{"date":269,"type":21},"2027-06-30",{"name":38,"class":39},{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":278,"enrollmentInfo":279,"targetDuration":4,"studyType":22,"phases":281,"briefSummary":282,"conditions":283,"keywords":288,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":290,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":40},"100587993","healing-hearts-of-hospitalized-patients-100587993","NCT06935604","Healing Hearts of Hospitalized Patients","Healing Hearts of Hospitalized Patients With Virtual Reality: A Pragmatic, Crossover Trial","Inclusion Criteria:\n\n* Adults aged 18 years and above\n* Able to provide informed consent\n* Able to follow verbal instructions\n* Adequate motor skills for upper extremities to operate VR equipment\n* Clinically stable\n* English speaking\n* Willing to participate in mindfulness activities\n\nExclusion Criteria:\n\n* Severe cognitive impairment\n* Clinically unstable\n* Facial trauma prohibiting headset use\n* Physical limitations in facial, neck, upper extremities that hinder use of VR equipment\n* History of seizures or other neurological conditions\n* Severe motion sickness\n* Active nausea\n* Severe visual impairment\n* Severe cognitive impairment","99 Years",{"count":280,"type":21},42,[24],"The study aims to evaluate the impact of a bedside-delivered virtual reality (VR) mindfulness experience on well-being and psychosocial outcomes among hospitalized adult patients compared to standard of care (SOC; no added mindfulness intervention).",[284,285,286,287],"Well-Being, Psychological","Anxiety","Affect","Relaxation",[289],"Virtual Reality",{"date":175,"type":32},{"date":292,"type":32},"2026-05-07",{"date":294,"type":21},"2027-05-31",{"name":38,"class":39},{"id":297,"slug":298,"hasResults":12,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":302,"eligibilityCriteria":303,"healthyVolunteers":12,"sex":17,"minAge":304,"maxAge":233,"enrollmentInfo":305,"targetDuration":4,"studyType":22,"phases":307,"briefSummary":308,"conditions":309,"keywords":311,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":315,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":40},"100586949","a-novel-auditory-application-for-distraction-in-pediatric-patients-100586949","NCT06922032","A Novel Auditory Application for Distraction in Pediatric Patients","A Novel Auditory Application for Distraction in Pediatric Patients: A Pilot Feasibility and Acceptability Study","Mystic Pet","Inclusion Criteria:\n\n* Between 4-17 years\n* English speaking participants\n\nExclusion Criteria:\n\n* Legal guardian not present to obtain consent\n* Child with hearing impairment\n* Child with a significant neurological condition, or major developmental disability\n* Child with facial abnormalities or injuries prohibiting use of headsets\n* Nausea at the time of recruitment,\n* A history of severe motion sickness,\n* A history of seizures","4 Years",{"count":306,"type":21},20,[24],"This mixed-methods study seeks to evaluate the feasibility of Mystic Pets software and hardware within the pediatric population. This study will take place at Lucile Packard Children's Hospital (Stanford University, Palo Alto, CA).",[310],"Emotional Distress",[312,313,314],"Game engagement","Awe","Procedural Distraction",{"date":175,"type":32},{"date":317,"type":21},"2026-12-01",{"date":319,"type":21},"2028-01-30",{"name":38,"class":39},{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":69,"sex":17,"minAge":18,"maxAge":328,"enrollmentInfo":329,"targetDuration":4,"studyType":22,"phases":331,"briefSummary":332,"conditions":333,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":4},"100652094","evaluating-food-messaging-campaigns-for-young-adults-100652094","NCT07768488","Evaluating Food Messaging Campaigns for Young Adults","Evaluating a Counter-marketing Campaign to Improve Diet Quality Among Young Adults","Inclusion Criteria:\n\n* 18-29 years old\n* Reside in the US\n* Speak English\n* Use Instagram 3-4 times per week or more\n* Consume sugary drinks 5-6 times per week or more and consume sweet and salty snacks 5-6 times per week or more\n\nExclusion Criteria:\n\n* Younger than 18 years or older than 29 years\n* Do not reside in the US\n* Do not speak English\n* Use Instagram less than 3-4 times per week\n* Consume sugary drinks less than 5-6 times per week or consume sweet and salty snacks less than 5-6 times per week","29 Years",{"count":330,"type":21},750,[24],"This study aims to determine whether online social media campaigns improve diet quality among young adults. Young adults will be exposed to one of three social media campaigns.",[334,335,336,337,338,339],"Social Media","Diet Quality","Diet Intervention","Communication","Young Adults","Nutrition","2026-08-14",{"date":218,"type":32},{"date":343,"type":21},"2027-09",{"date":345,"type":21},"2029-04",{"name":38,"class":39},{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":69,"sex":17,"minAge":18,"maxAge":328,"enrollmentInfo":354,"targetDuration":4,"studyType":22,"phases":356,"briefSummary":357,"conditions":358,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":360,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":40},"100652035","young-adult-food-messaging-experiment-100652035","NCT07768462","Young Adult Food Messaging Experiment","An Experiment Evaluating the Effectiveness of Counter-marketing Food Messages Among Young Adults","Inclusion Criteria:\n\n* Age between 18-29 years\n* Reside in the United States\n* Consume at least 5-6 servings per week of sugary drinks and 5-6 servings per week of sweet and salty snacks\n\nExclusion Criteria:\n\n* Younger than 18 or older than 29 years\n* Reside outside of the United States\n* Consume less than 5-6 servings per week of sugary drinks or less than 5-6 servings per week of sweet and salty snacks",{"count":355,"type":21},645,[24],"The primary objective of this study is to identify the food counter-marketing messages (i.e., messages that describe deceptive marketing tactics used by food companies) that are perceived as most effective among young adults.",[335,359,337],"Young Adult Health",{"date":218,"type":32},{"date":362,"type":21},"2027-01-08",{"date":364,"type":21},"2027-01-16",{"name":38,"class":39},{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":4,"eligibilityCriteria":372,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":373,"targetDuration":4,"studyType":22,"phases":375,"briefSummary":377,"conditions":378,"keywords":380,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":391},"100650257","phase-3-rb-pdt-for-fusarium-keratitis-the-lumiere-study-100650257","NCT07743489","RB-PDT for Fusarium Keratitis: The LUMIERE Study","Light for Ulcer Management by Infection Elimination and Resistance Enhancement (LUMIERE)","Inclusion Criteria:\n\n* Presence of culture positive fusarium fungal keratitis\n* Age over 18 years\n* Moderate to severe vision loss, defined as Snellen visual acuity of 20\u002F40 (6\u002F12) to 20\u002F400 (6\u002F120)\n* Corneal thickness ≥350 µm, as measured on AS-OCT\n* Basic understanding of the study as determined by the physician\n* Commitment to return for follow up visits\n\nExclusion Criteria:\n\n* History of hypersensitivity to Rose Bengal\n* Evidence of concomitant infection on exam, gram stain, or confocal microscopy (i.e. herpes, both bacteria and acanthamoeba on gram stain)\n* History of intraocular surgery within the last three months\\*\n* Impending or frank perforation at recruitment\n* Involvement of sclera at presentation\n* Presence of desmestocele at recruitment\n* Non-infectious or autoimmune keratitis\n* History of corneal transplantation\n* Pinhole visual acuity worse than 20\u002F200 in the unaffected eye\n* Participants who are decisionally and\u002For cognitively impaired",{"count":374,"type":21},434,[376],"PHASE3","This is a multicenter trial with recruitment planned at ophthalmology clinics specializing in corneal diseases in India, Brazil, and at Stanford University and Bascom Palmer Eye Institute in the United States. Fusarium keratitis is common in tropical and subtropical regions like Florida, India and Brazil, which will facilitate access to the required number of participants. The study aims to recruit a total of 434 participants (217 per group).",[379],"Fusarium Keratitis",[381,382,383],"fusarium keratitis","rose bengal","RB-PDT","2026-08-13",{"date":218,"type":32},{"date":387,"type":21},"2027-01",{"date":389,"type":21},"2030-01",{"name":38,"class":39},4,{"id":393,"slug":394,"hasResults":12,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":399,"enrollmentInfo":400,"targetDuration":4,"studyType":22,"phases":401,"briefSummary":403,"conditions":404,"keywords":412,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":415,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":40},"100616220","phase-1-tacrolimus-targeted-immunosuppression-cessation-in-allogeneic-hct-100616220","NCT07302776","TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT","TACTICAL: TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT","Inclusion Criteria:\n\n* Eligible diseases:\n\n  * Acute myeloid leukemia (AML) in complete remission (CR), CR with incomplete hematologic recovery (CRi), or MLFS.\n  * Myelodysplasic syndrome (MDS) myelodysplastic syndromes eligible for alloHSCT based on IPSS-M of intermediate or higher, or IPSS-R of intermediate or higher, or refractory disease to standard growth factor or hypomethylating agent-based therapy\n  * Myelofibrosis (MF)\n  * Chronic myeloid leukemia (CML) in chronic phase with a prior history of accelerated phase or blast crisis or CML in chronic phase refractory to standard TKI therapy\n  * Chronic myelomonocytic leukemia (CMML)\n* Age ≥ 18 and ≤ 80 years at the time of enrollment.\n* Planned for first myeloablative or reduced intensity allogenic transplant using a conditioning regimen listed in Appendix B.\n* Has a related or unrelated donor available who is 8\u002F8 HLA match at HLA-A, -B, -C, and -DRB1, all typed using DNA-based high-resolution methods.\n* Estimated glomerular filtration rate (eGFR) ≥ 50 mL\u002Fminute or creatinine \\\u003C 2 mg\u002FdL.\n\nCardiac ejection fraction at rest ≥ 45% or shortening fraction of ≥ 27% by echocardiogram or radionuclide scan (MUGA).\n\n* Diffusing capacity of the lung for carbon monoxide (DLCO) (adjusted for hemoglobin) ≥ 50%.\n* Total bilirubin \\\u003C 2 times upper limit of normal (ULN) (patients with Gilbert's syndrome may be included once hemolysis has been excluded).\n* Karnofsky Performance Score ≥70%\n* Negative serum or urine beta-HCG test in females of childbearing potential (FCBP) within 3 weeks of enrollment.\n\nA female of childbearing potential (FCBP) is a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).\n\n-Ability to understand and the willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Prior allogeneic HCT.\n* Planned donor lymphocyte infusion (DLI).\n* Recipient positive anti-donor HLA antibodies against a mismatched allele in the selected donor determined by either:\n\n  1. Positive crossmatch test of any titer (by complement-dependent cytotoxicity or flow cytometric testing), or\n  2. Presence of anti-donor HLA antibody to any of the following HLA loci: HLA-A, -B, -C, -DRB1, -DQB1, -DQA1, -DPB1, or -DPA1, with mean fluorescence intensity (MFI) \\>1000 by solid phase immunoassay.\n* Uncontrolled bacterial, viral, or fungal infections at time of enrollment including known, active tuberculosis infection.\n* Seropositive for HIV-1 or -2, HTLV-1 or -2, Hepatitis B sAg, and\u002For Hepatitis C antibody.\n\n  \\*History of hepatitis B or hepatitis C is permitted if viral load is undetectable per quantitative PCR and\u002For NAT.\n\nKnown allergy or hypersensitivity to planned GVHD prophylactic medications including PTCy, tacrolimus\n\n* Any uncontrolled autoimmune disease requiring active immunosuppressive treatment.\n* Concurrent malignancy diagnosed within 12 months of enrollment, except non-melanoma skin cancers or other early-stage solid tumors that have been curatively resected or treated to curative intent. Patients with history of low grade concurrent blood cancers that are controlled will be eligible.\n* Females of childbearing potential (FCBP) or men who have sexual contact with FCBP unwilling to use effective forms of birth control or abstinence for one year after transplantation.\n\n(FCBP definition: A female of childbearing potential (FCBP) is a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).\n\n-Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the recipient's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results.\n\n\\* All subject files must include supporting documentation to confirm subject eligibility.","80 Years",{"count":20,"type":21},[402],"PHASE1","The purpose of this study is to test the feasibility and safety of early cessation of tacrolimus following allogeneic hematopoietic cell transplantation (HCT). Post-HCT tacrolimus is given to prevent graft-vs-host-disease (GVHD), but with the use of post-transplant cyclophosphamide (PTCy), the modern approach to GVHD prevention, GVHD rates have reduced markedly.",[405,406,407,408,409,410,411],"GVHD","Hematopoietic Cell Transplantation (HCT)","Acute Myeloid Leukemia (AML)","Myelodysplastic Syndromes","Myelofibrosis (MF)","Chronic Myeloid Leukemia (CML)","Chronic Myelomonocytic Leukemia (CMML)",[413,414],"Post-Hematopoietic Cell Transplant (HCT) tacrolimus","hematopoietic cell transplantation (HCT)",{"date":218,"type":32},{"date":417,"type":32},"2026-07-21",{"date":419,"type":21},"2028-02",{"name":38,"class":39},{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":427,"eligibilityCriteria":428,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":429,"targetDuration":4,"studyType":22,"phases":431,"briefSummary":432,"conditions":433,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":437,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":443},"100460465","phase-3-descemet-endothelial-thickness-comparison-trial-ii-100460465","NCT05275972","Descemet Endothelial Thickness Comparison Trial II","Descemet Endothelial Thickness Comparison Trials (DETECT I & II)","DETECT II","Inclusion Criteria:\n\n* Dysfunctional endothelium from FECD with few guttata extending beyond 4.5 mm\n* Peripheral endothelial cell count \\>1000 cells\u002Fmm2 in at least one quadrant\n* Good surgical candidate for either procedure as determined by the surgeon\n* Willingness to participate\n* Age greater than 18 years\n\nExclusion Criteria:\n\n* Aphakia, anterior chamber IOL or scleral fixated IOL in study eye prior to or anticipated during EK\n* Pre-operative central sub-epithelial or stromal scarring that the investigator believes is visually significant and could impact post-operative stromal clarity assessment\n* Other primary endothelial dysfunction such as PPMD\n* Visually significant optic nerve or macular pathology\n* Hypotony (Intraocular pressure \\\u003C10mmHg)\n* Any prior intraocular surgery other than cataract surgery\n* \\>3 clock hours of ANY anterior or posterior synechiae\n* \\>1 quadrant of stromal corneal vascularization\n* Inability to comply with post-operative instructions (i.e. unable to position)\n* Pregnancy",{"count":430,"type":21},60,[376],"Descemet Endothelial Thickness Comparison Trial (DETECT) II is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 60 patients with Fuchs endothelial dystrophy to DMEK versus Descemet Stripping Only (DSO) with adjunctive Ripasudil.",[434,435,436],"Fuchs","Fuchs Dystrophy","Fuchs' Endothelial Dystrophy",{"date":218,"type":32},{"date":439,"type":32},"2023-01-23",{"date":441,"type":21},"2028-10-30",{"name":38,"class":39},8,{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":448,"acronym":4,"eligibilityCriteria":449,"healthyVolunteers":12,"sex":17,"minAge":70,"maxAge":450,"enrollmentInfo":451,"targetDuration":4,"studyType":22,"phases":453,"briefSummary":454,"conditions":455,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":458,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":462,"locationsCount":40},"100433886","phase-1-the-effect-of-micro-fragmented-adipose-tissue-mfat-on-shoulder-osteoarthritis-100433886","NCT04929951","The Effect of Micro Fragmented Adipose Tissue (MFAT) on Shoulder Osteoarthritis","Inclusion Criteria:\n\n* Age between 25 and 75 years-old\n* Diagnosis of pre-existing osteoarthritis of the glenohumeral joint\n* Working understanding of the English language and able to fully understand the procedure\n* Capable of providing informed consent\n* Able to complete online, in-person or phone surveys for the purposes of follow-up\n* Capable of understanding pre- and post-procedure care instructions\n* Ambulatory at baseline\n* Previous trial and failure of conservative therapy consisting of a minimum of 6 weeks of physical therapy and trial of anti-inflammatory medications if not contraindicated, with or without concomitant bracing and\u002For injections.\n\nExclusion Criteria:\n\n* Age \\\u003C 25 or \\> 75 years old\n* Radiographs demonstrating either no, little osteoarthritis, severe(bone on bone) osteoarthritis\n* Prior total or partial joint replacement surgery or surgery involving cartilage regeneration\n* Previous cortisone, PRP or Hyaluronic acid intra-articular injection within the last 3 months\n* Co-morbidity with the rheumatologic condition, inflammatory arthritis\n* Currently undergoing immunomodulatory therapy\n* Uncontrolled endocrine disorder\n* BMI \\>40 or joint space not visible by ultrasound\n* Current diagnosis of osteomyelitis, human immunodeficiency virus (HIV-1, -2) and\u002For hepatitis C (HCV), infection, and poorly controlled diabetes (HgA1C \\>7.0)\n* Pregnancy or planned pregnancy\n* previous stem cell injection into treatment joint\n* Patient scheduled to undergo any concomitant shoulder surgical procedures or other surgery which may affect outcomes.\n* Coagulopathy or anticoagulant treatment\n* Chronic pain involving multiple body parts or opioid medication management\n* Diagnosis of fibromyalgia\n* Concomitant massive(2 tendons with retraction), complete rotator cuff tendon tear","75 Years",{"count":452,"type":21},48,[402],"This is a non-surgical trial comparing the clinical and functional outcomes of patients with osteoarthritis treated with Intra-articular injection of Micro Fragmented Adipose Tissue versus conventional therapy of intra-articular injection of corticosteroid.",[456,457],"Osteoarthritis Shoulder","Shoulder Pain",{"date":218,"type":32},{"date":460,"type":32},"2022-07-28",{"date":148,"type":21},{"name":38,"class":39},{"id":464,"slug":465,"hasResults":12,"nctId":466,"briefTitle":467,"officialTitle":468,"acronym":4,"eligibilityCriteria":469,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":470,"targetDuration":4,"studyType":22,"phases":472,"briefSummary":473,"conditions":474,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":479,"completionDateStruct":480,"leadSponsor":482,"locationsCount":4},"100630164","phase-1-il6-receptor-inhibitor-iwith-belumosudil-for-the-treatment-of-belumosudil-refractory-cgvhd-100630164","NCT07484113","IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD","IL6-receptor Inhibitor in Combination With Belumosudil for the Treatment of Belumosudil-refractory Chronic Graft-versus-host Disease (cGVHD)","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Active cGVHD and currently receiving belumosudil with inadequate response (defined as disease progression at any time or failure to achieve at least a partial response after a minimum of 3 months of belumosudil therapy, and for whom the treating physician believes a new systemic therapy is required).\n3. Persistent cGVHD manifestations and systemic therapy indicated.\n4. Karnofsky Performance Score of ≥ 60.\n\n   Laboratory Parameters:\n5. Absolute neutrophil count ≥ 1.5 x 109\u002FL\n6. Platelet count ≥ 50 x 109\u002FL\n7. ALT and AST \\\u003C 1.5 × ULN\n8. Total bilirubin ≤ 1.5 × ULN\n9. Glomerular filtration rate (GFR) ≥ 30 ml\u002Fmin\u002F1.73m2\n\n   General Criteria:\n10. Negative urine pregnancy test at screening for females of childbearing potential.\n11. Sexually active females of childbearing potential must agree to use two accepted methods of contraception during treatment and for 3 months after their last dose.\n12. Sexually active male subjects with female partners of childbearing potential must agree to use two accepted methods of contraception and refrain from sperm donation during treatment and for at least 3 months after their last dose.\n\n14\\. Ability to provide written informed consent (or consent from legally authorized representative). 15. Minimum weight of 63 kg\n\nExclusion Criteria:\n\n1. Not on a stable systemic cGVHD treatments for at least 2 weeks prior to screening. (Note: Concomitant corticosteroids, calcineurin inhibitors, sirolimus are allowed. Systemic investigational GVHD treatments are not permitted).\n2. Histological relapse of the underlying cancer or post-transplant lymphoproliferative disease at the time of screening.\n3. Current treatment with ibrutinib or ruxolitinib. Prior treatment is allowed with a washout of at least 1 week prior to randomization.\n\n   General Criteria:\n4. Pregnant or breastfeeding.\n5. History or other evidence of severe illness or any other conditions that would make the subject, in the opinion of the sponsor-investigator, unsuitable for the study (such as malabsorption syndromes, poorly controlled psychiatric disease or coronary artery disease).\n6. Known active hepatitis B virus (HBV) or hepatitis C virus (HCV) or history of human immunodeficiency virus (HIV).\n7. Malignancy diagnosed within 3 years (other than malignancy for which transplant was performed), with the exception of:\n\n   1. Completely resected basal cell or squamous cell carcinoma of the skin\n   2. Carcinoma in situ of the cervix\n   3. Resected breast ductal carcinoma in situ\n   4. Prostate cancer with Gleason score \\\u003C6 and stable PSA over 12 months\n8. QTc(F) \\> 480 ms\n9. Sponsor-investigator deems subject unlikely to adhere to study procedures\u002Ftreatment.\n10. Investigational agent, device, or procedure within 28 days of first dose (or 5 half-lives, whichever longer).\n11. Active TB or a history of incompletely treated TB regardless of screening Quantiferon Result.",{"count":471,"type":21},10,[402],"A single-center, Phase 1, open-label, investigator-initiated clinical trial evaluating the safety, tolerability, and preliminary efficacy of sarilumab (anti-IL-6R) monotherapy as a rescue in adult patients with belumosudil-refractory chronic graft-versus-host disease (cGVHD).",[475],"cGVHD","2026-08-10",{"date":478,"type":32},"2026-08-12",{"date":59,"type":21},{"date":481,"type":21},"2028-05",{"name":38,"class":39},{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":4,"eligibilityCriteria":489,"healthyVolunteers":69,"sex":126,"minAge":18,"maxAge":490,"enrollmentInfo":491,"targetDuration":4,"studyType":492,"phases":4,"briefSummary":493,"conditions":494,"keywords":496,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":501,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":506,"locationsCount":40},"100628294","body-clocks---coordination-of-peripheral-and-central-oscillators-100628294","NCT07459764","Body Clocks - Coordination of Peripheral and Central Oscillators","Confluence of Sleep, Circadian Rhythms, and the Menstrual Cycle on Injury Risk in Women","Inclusion Criteria:\n\n* Regular menstrual cycle (21-35 days)\n* 18-30 years old\n\nExclusion Criteria:\n\n* Neuromuscular or neurodegenerative disease\n* Gut disorders\n* circadian sleep disorders\n* prescription medications affecting sleep\n* recovering from physical injury\n* taking hormonal birth control","30 Years",{"count":306,"type":21},"OBSERVATIONAL","The investigators are conducting an observational trial examining young women over the course of 28 days in which we are monitoring movement, sleep, heart rate, oxygen saturation, gut physiology, light, and menstrual cycle. The inter- and independence of the cyclicity of these variables with each other, the circadian cycle, the menstrual cycle, and the sleep cycle will be tested.",[495],"Circadian Dysregulation",[497,498,499,500],"sleep","circadian","menstrual","women's health",{"date":478,"type":32},{"date":503,"type":32},"2026-04-15",{"date":505,"type":21},"2026-11-30",{"name":38,"class":39},{"id":508,"slug":509,"hasResults":12,"nctId":510,"briefTitle":511,"officialTitle":512,"acronym":513,"eligibilityCriteria":514,"healthyVolunteers":69,"sex":17,"minAge":18,"maxAge":515,"enrollmentInfo":516,"targetDuration":4,"studyType":22,"phases":517,"briefSummary":518,"conditions":519,"keywords":522,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":539,"startDateStruct":540,"completionDateStruct":541,"leadSponsor":543,"locationsCount":40},"100610361","using-a-personalized-decision-support-tool-to-help-people-with-type-1-diabetes-manage-exercise-100610361","NCT07226583","Using a Personalized Decision Support Tool to Help People With Type 1 Diabetes Manage Exercise","Net-IOB & Exercise Toolkit Pilot Trial: Randomized, Crossover Evaluation of a Behavioral Decision Support Advisor to Improve Glycemic Safety During and After Exercise in Adults With Type 1 Diabetes (NEXT)","NEXT","Inclusion Criteria Inclusion Criteria: All Participants (Type 1 Diabetes and Healthy Control Groups)\n\n* Adults between the age of 18-60 years\n* Able to perform moderate intensity walking for 60 minutes (target 40-60% age-predicted maximal heart rate).\n* Willing and able to comply with study procedures, including supervised exercise visits and device wear\n* Able to provide written informed consent\n\nInclusion Criteria: Type 1 Diabetes Group Only\n\n* Clinical diagnosis of type 1 diabetes for \\>1 year, based on the investigator's clinical judgement\n* Current use of continuous subcutaneous insulin infusion with Tandem Control-IQ and a compatible continuous glucose monitor (CGM) for \\>1 month prior to enrollment\n* Stable insulin delivery regimen, with no planned changes to insulin pump settings or insulin dosing strategy during the study period\n* Consistent CGM use during the month prior to enrollment (\\>80% data availability)\n\nInclusion Criteria: Health Control Group Only\n\n* No diagnosis of diabetes or other disorders of glucose metabolism\n* Not using insulin or glucose-lowering medications\n\nExclusion Criteria Exclusion Criteria: All Participants\n\n* Intercurrent illness or medical condition that precludes safe participation in moderate-intensity exercise (e.g., unstable cardiopulmonary disease, uncontrolled arrhythmia, or uncontrolled hypertension), as previously assessed by the participant's primary care physician\n* Known coronary artery disease with symptoms limiting moderate physical activity, or history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the past 12 months\n* Pregnancy, lactation, or plans to become pregnant during the study period\n* Renal insufficiency with estimated GFR \\\u003C45 mL\u002Fmin\u002F1.73 m², dialysis dependence, or adrenal insufficiency\n* Concurrent participation in another interventional drug or device study within 30 days prior to enrollment\n* Inability to comply with study procedures or safety requirements (e.g., inability to achieve target heart-rate zone, attend scheduled visits, or enable required device data access), or otherwise deemed unsuitable by the investigator\n\nExclusion Criteria: Type 1 Diabetes Group Only\n\n* Use of non-CSII insulin delivery, including long-acting injectable or inhaled insulin, during the study period\n* Use of medications with potential to substantially affect glycemia (e.g., SGLT-2 inhibitors, GLP-1 receptor agonists, or GIP agonists), unless on a stable regimen with no planned changes during the study\n* Use of systemic corticosteroids within 4 weeks prior to participation\n* History of severe hypoglycemia (requiring third-party assistance) or diabetic ketoacidosis within the prior 6 months","60 Years",{"count":306,"type":21},[24],"This study evaluates a clinician-facing decision-support toolkit designed to assist adults with type 1 diabetes in preparing for moderate-intensity exercise. The netIOB \\& Exercise Toolkit (NEXT) integrates recent glucose data and insulin delivery history to provide individualized suggestions regarding exercise timing, insulin adjustments, and carbohydrate intake.\n\nAdults with type 1 diabetes will complete three supervised exercise sessions under different pre-exercise guidance approaches:\n\n(A) published consensus-based standard-of-care guidance, (B) usual personal care routines, and (C) guidance informed by the NEXT Toolkit.\n\nA healthy adult control group will complete a single supervised exercise session to provide comparative physiologic data.",[520,521],"Type 1 Diabetes Mellitus","Exercise Physiology",[523,524,525,526,527,528,529,530,531,532,533,534,535,536,537,538],"Type 1 Diabetes","T1D","T1DM","Continuous Glucose Monitoring","Insulin Dosing","CGM","Insulin Pump","Exercise","carbohydrate Intake","closed-loop system","hybrid closed-loop","CKM","Continuous Ketone Monitoring","Glucose Metabolism","Ketone Metabolism","Exercise Metabolism",{"date":478,"type":32},{"date":83,"type":21},{"date":542,"type":21},"2027-02",{"name":38,"class":39},{"id":545,"slug":546,"hasResults":12,"nctId":547,"briefTitle":548,"officialTitle":549,"acronym":4,"eligibilityCriteria":550,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":551,"targetDuration":4,"studyType":22,"phases":553,"briefSummary":554,"conditions":555,"keywords":564,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":571,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":576,"locationsCount":40},"100542274","phase-1-autologouscd22-chimeric-antigen-receptor-cart-cells-in-wrecurrentrefractory-b-cell-lymphomas-100542274","NCT06340737","AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w\u002FRecurrent\u002FRefractory B Cell Lymphomas","Phase Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults With Recurrent or Refractory B Cell Lymphomas","Inclusion Criteria:\n\n* Disease: Must have histologically confirmed disease as defined by WHO 2016\\[117\\] of one of the following:\n\nFollicular Lymphoma, grade 1-3a\n\n1. Relapsed or refractory disease after at least 2 lines of systemic therapy. Prior therapy must have included an anti-CD20 monoclonal antibody combined with systemic therapy (single-agent anti- CD20 antibody does not count as line of therapy for eligibility nor does local radiation). Anti-CD20 antibody is not required for participants with CD20 negative disease. A systemic therapy includes, but is not limited to: Bendamustine, CHOP, CVP, CART therapy, lenalidomide, or platinum-based chemotherapy.\n2. Relapsed or progressive disease within 24 months of initiation of the initial course of chemotherapy (also known as progression of disease within 24 months POD24). Initial treatment must have included an anti-CD20 monoclonal antibody (unless CD20 negative) plus either Bendamustine, CHOP or CVP (R-Chemo). Must have completed 3 or more cycles of R-Chemo. Progression is measured from the initial day of treatment of the first cycle of R-Chemo. In the case of those who received anti-CD20 monoclonal antibody monotherapy previously and then received R-Chemo are also eligible if they are POD24, and progression is measured from the initial day of treatment of the first cycle of R-Chemo and not from the initial day of anti-CD20 monoclonal antibody monotherapy.\n\nMantle Cell Lymphoma 1. Relapsed or refractory disease after at least 2 lines of systemic therapy. Prior therapy must have included an anti-CD20 monoclonal antibody combined with systemic therapy. Anti-CD20 antibody is not required for participants with CD20negative disease.\n\n2\\. Participants who have received an anti-CD20 monoclonal antibody in combination with chemotherapy AND a Bruton's Tyrosine Kinase inhibitor as a single line of therapy are also eligible.\n\nHairy cell leukemia (HCL)\n\n1. Diagnosis of HCL and require treatment as defined by having HCL-related anemia (hemoglobin \\\u003C11 g\u002FdL), thrombocytopenia (platelets\\\u003C100 x 10\\^9 \u002FL), or neutropenia (absolute neutrophil count below 1.5 x 10\\^9\u002FL); symptomatic splenomegaly or adenopathy; or other constitutional symptoms directly related to HCL;\n2. Must have progressed or been refractory to 2 lines of therapy including a purine nucleoside analog.\n\nLymphoplasmacytic lymphoma (Waldenstrom macroglobulinemia (WM)) - participants must meet all eligibility criteria listed\n\n1\\. Must have confirmed diagnosis of WM based on Second International Workshop on WM 2. Relapsed or refractory disease after 2 or more lines of therapy\n\n1\\. Prior therapies must include a i. BTKi ii. either chemotherapy and\u002For proteasome inhibitor 3. Requires treatment based on the recommendations from the Second International Workshop on WM 4. Requires the presence of serum IgM that is at least 2 times the upper limit of normal 5. Patients cannot require plasmapheresis for symptomatic hyperviscosity. 6. Patients cannot have symptomatic central nervous system involvement (Bing-Neel syndrome) that would prevent the assessment of neurotoxicity 7. Patients cannot have transformed to large B cell lymphoma Burkitt lymphoma (BL)\n\n1\\. Relapsed or refractory to front line chemoimmunotherapy; Participants with high-grade B-cell lymphoma with MYC and BCL2 and\u002ForBCL6 rearrangements will be excluded.\n\nMarginal zone lymphoma (MZL)\n\n1\\. Must have received 2 prior lines of therapy including rituximab in combination with chemotherapy or a BTKi\n\nHistologically confirmed Large B-cell lymphoma (LBCL) by WHO 2008 including:\n\ni. DLBCL not otherwise specified; DLBCL associated with chronic inflammation; Epstein Barr virus (EBV)+ DLBCL of the elderly; OR ii. primary mediastinal (thymic) large B cell lymphoma; OR iii. transformation of follicular lymphoma, marginal zone lymphoma or chronic lymphocytic leukemia\u002Fsmall lymphocytic lymphoma to DLBCL; OR iv. Follicular Lymphoma Grade 3B\n\n• Subjects with DLBCL, Follicular Lymphoma Grade 3B -or-\n\nSubjects with transformed FL and MZL who HAVE NOT received chemotherapy prior to transformation:\n\n1\\) Must have received an anthracycline regimen and an anti CD20 monoclonal antibody (unless documented CD20-negative) and be refractory or relapsed after second line of LBCL treatment. Subjects with a partial response to second line therapy must be ineligible for autologous transplant.\n\n* Subjects with transformed FL and MZL who HAVE received anthracycline-containing chemotherapy prior to transformation must have progressed, had SD or recurred with transformed disease after initial treatment for LBCL:\n\n  1. Must have progressed, had SD, or recurred with transformed disease after initial treatment for LBCL\n\n     Note: T cell\u002Fhistiocyte rich large B cell lymphoma is not eligible\n\n     The following criteria apply to all participants unless otherwise noted:\n\n  2\\. Measurable Disease:\n  1. a. Participants with Follicular Lymphoma, Mantle Cell Lymphoma, Burkitt Lymphoma and Marginal Zone Lymphoma must have measurable disease according to the revised IWG Response Criteria for Malignant Lymphoma. Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy.\n\n     b. If participants with Follicular Lymphoma, Mantle Cell Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphoma, and Large B cell Lymphoma that do not have measurable disease according to the revised IWG Response Criteria for Malignant Lymphoma, but have disease that is greater than 2% of events by flow cytometry in the peripheral blood or bone marrow will be eligible\n  2. c. Participants with Hairy Cell Lymphoma must have presence of leukemic cells in the bone marrow or blood stream.\n  3. d. Participants with Lymphoplasmacytic lymphoma must have the presence of serum IgM that is at least 2 times the upper limit of normal.\n\n  3\\. CD22 expression, at any level: Participants must have archival tissue available for analysis of CD22 expression or must be willing to undergo biopsy of easily accessible disease.\n\n  4\\. Participants who have progressed or relapsed after prior autologous OR allogeneic SCT must be at least 100 days post-transplant, have no evidence of GVHD, and have been without immunosuppressive drugs at least 30 days.\n\n  5\\. Meet required prior therapy washout windows prior to leukapheresis (see inclusion criteria for leukapheresis for details).\n\n  6\\. Participants with prior CAR therapy must be at least 30 days post CAR infusion and have \\\u003C 5% CD3+ cells express the previous CAR prior to apheresis, if a validated assay is available.\n\n  7\\. Toxicities from prior therapy stable or resolved (except for clinically non-significant toxicity and cytopenias covered in footnote).\n\n  8\\. Age ≥ 18 years of age. 9. Adequate performance status (ECOG 0, 1, or 2; or Karnofsky \\> 60%) 10. Adequate organ and marrow function as defined by:\n\n  \\- ANC ≥ 750\u002FuL\n  * Platelet count ≥ 50,000\u002FuL\n  * ALC ≥ 150\u002FuL\n  * Adequate renal, hepatic, pulmonary and cardiac function defined as: Creatinine \\\u003C 2 mg\u002FdL OR Creatinine clearance (as estimated by Cockcroft Gault Equation) ≥ 45 mL\u002Fmin, Serum ALT or AST ≤ 10 x ULN (except in participants with liver involvement by lymphoma), Total bilirubin ≤ 1.5 mg\u002Fdl, except in participants with Gilbert's syndrome, Cardiac left ventricular ejection fraction ≥ 45%, no evidence of clinically significant pericardial effusion as determined by an Echocardiogram.\n  * No clinically significant pleural effusion or ascites\n  * Baseline oxygen saturation \\> 92% on room air ANC Platelet ALC Cr CreatCl AST\u002FALT Bilirubin LVEF O2 Sat\n  * 11\\. Participants with CNS involvement or a history of CNS involvement are eligible only in the absence of neurologic symptoms that may mask or interfere with neurological assessment of toxicity 12. Females of childbearing potential must have negative pregnancy test. 13. Females of child-bearing potential and males of child-fathering potential must be willing to practice birth control from time of enrollment and for 4 months post preparative lymphodepletion regimen or as long as CAR cells are detectable.\n\n    14\\. Must be able to provide informed consent (LAR is permitted if participant able to provide verbal assent).\n\nA participant will not be excluded because of pancytopenia ≥ Grade 3 if it is felt by the investigator to be due to underlying disease.\n\nExclusion Criteria:\n\n* Presence rapidly progressive disease that in the estimation of the investigator and sponsor would compromise ability to complete study therapy.\n\n  2\\. History or current other malignancies, apart from non-melanoma skin cancer, low-grade untreated prostate cancer under observation, or carcinoma in situ, unless disease free for at least 3 years, or in remission 1-2 years and Principal Investigator assesses other malignancy as unlikely to return within 1 year or interfere with CAR T cell safety\n\n  3\\. Presence of active fungal, bacterial, viral or other infection requiring intravenous antimicrobials. Simple UTI or uncomplicated bacterial pharyngitis is permitted if responding to active treatment.\n\n  4\\. Ongoing HIV, HBV, or HCV infection. History of HBV or HCV is permitted if viral load is undetectable by qPCR and\u002For nucleic acid testing.\n\n  5\\. Active cerebrovascular ischemic\u002Fhemorrhage, dementia, cerebellar disease, or autoimmune disease with CNS involvement that in investigator's judgement impair ability to evaluate neurotoxicity.\n\n  6\\. History of MI, cardiac angioplasty or stenting, unstable angina or other clinically significant cardiac disease within 12 months of enrollment.\n\n  7\\. Severe, immediate hypersensitivity reaction attributed to compounds of similar chemical or biologic composition to any agents used in study.\n\n  8\\. Is pregnant or breastfeeding.\n\n  9\\. Active primary immunodeficiency or history of autoimmune disease (e.g. Crohn's disease, rheumatoid arthritis, systemic lupus) requiring systemic immunosuppression\u002Fsystemic disease modifying agents within the last 2 years.\n\n  10\\. May NOT, in investigator's judgment, have any medical condition likely to interfere with assessment of safety or efficacy, or be likely to complete all protocol-required visits and procedures.",{"count":552,"type":21},148,[402],"This is a non-randomized clinical trial to evaluate the safety and efficacy of CD22CART administered after lymphodepleting chemotherapy in adults with relapsed \u002F refractory B Cell Lymphomas. All evaluable participants will be followed for overall survival (OS), progression free survival (PFS), and duration of response (DOR). An evaluable participant is one who completes leukapheresis, lymphodepleting chemotherapy and CART infusion.",[556,557,558,559,560,561,562,563],"Follicular Lymphoma","Mantle Cell Lymphoma","Hairy Cell Leukemia","Lymphoplasmacytic Lymphoma","Burkitt Lymphoma","Marginal Zone Lymphoma","Waldenstrom Macroglobulinemia","Large B-cell Lymphoma",[565,566,567,568,569,570],"lymphoma","leukemia","lymphodepleting chemotherapy","relapsed","refractory","systemic therapy",{"date":478,"type":32},{"date":573,"type":32},"2024-03-29",{"date":575,"type":21},"2031-04",{"name":38,"class":39},{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":4,"eligibilityCriteria":583,"healthyVolunteers":12,"sex":126,"minAge":18,"maxAge":450,"enrollmentInfo":584,"targetDuration":4,"studyType":22,"phases":585,"briefSummary":586,"conditions":587,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":590,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":595,"locationsCount":40},"100467433","lympha-procedure-for-the-prevention-of-lymphedema-after-axillary-lymphadenectomy-100467433","NCT05366699","LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy","A Randomized Clinical Trial of the LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy","Inclusion Criteria:\n\n* Ages 18 to 75 years (inclusive)\n* Patients undergoing unilateral or bilateral breast cancer related axillary lymphadenectomy\n* Free of distant metastasis in preoperative screening\n* Histology results of axillary lymph nodes could be either Negative or Positive\n* Patients who undergo preoperative chemotherapy can be included\n* Willingness and ability to provide written informed consent\n* Willingness and ability to comply with all study procedures\n\nExclusion Criteria:\n\n* Primary lymphedema of the affected upper limb\n* Secondary lymphedema of the affected limb prior to the lymphadenectomy\n* Radiotherapy at the axilla before the study \u002F surgery\n* Allergic reaction to porcine collagen or ICG\n* Receiving radiation therapy to the involved nodal basin in a period less than 4 weeks after the surgery\n* Concurrent participation in a clinical trial of any other investigational drug or therapy, regardless of indication, within 1 month before screening\n* Other medical condition that could lead to limb edema, such as (but not limited to primary lymphedema or acute venous thrombosis\n* Other medical condition that could result in symptoms overlapping those of lymphedema in the affected limb (e.g., pain, swelling, decreased range of motion)\n* Either of the following, at the time of baseline evaluation: ipsilateral:contralateral limb volume ratio\\>1.1 or R0 bioimpedance ratio \\> 1.106 when the nondominant limb is at risk, and 1.134 when the dominant limb is at risk.\n* Life expectancy \\\u003C 2 years for any reason\n* Pregnancy or nursing\n* Substance abuse (such as alcohol or drug abuse) within 6 months prior to screening\n* Severe psychiatric disease\n* Significant or chronic renal insufficiency (defined as serum creatinine \\> 2.5 mg\u002FdL or an estimated glomerular filtration rate \\[eGFR\\] \\\u003C 30 mL\u002Fmin at screening) or requires dialytic support\n* Hepatic dysfunction, defined as alanine transaminase (ALT) or aspartate transaminase (AST) levels \\> 3 × upper limit of the normal range (ULN) and\u002For bilirubin level \\> 2 × ULN at screening\n* Absolute neutrophil count \\\u003C 1500 mm3 at screening\n* Hemoglobin concentration \\\u003C 9 g\u002FdL at screening\n* Any reason (in addition to those listed above) that, in the opinion of the investigator, precludes full participation in the study",{"count":129,"type":21},[24],"Lymphedema is a chronic, progressive, and debilitating condition that occurs with disruption or obstruction of the lymphatic system, which commonly occurs a result of breast cancer therapy. The purpose of this study is to determine if the use of a low risk lymphatic reconstruction procedure at the time of axillary lymph node dissection will reduce the risk of developing lymphedema.\n\nAdditionally, to determine if this procedure improves objective outcomes of lymphedema and patient quality of life",[588,589],"Lymphedema, Breast Cancer","Lymphedema",{"date":478,"type":32},{"date":592,"type":32},"2021-09-10",{"date":594,"type":21},"2030-06-01",{"name":38,"class":39},{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":4,"eligibilityCriteria":602,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":603,"targetDuration":4,"studyType":22,"phases":604,"briefSummary":605,"conditions":606,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":611,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":615,"locationsCount":40},"100462509","aromatherapy-inhaler-use-for-hsct-distress-100462509","NCT05302583","Aromatherapy Inhaler Use for HSCT Distress","Aromatherapy Inhaler Use for Hematopoietic Stem Cell Transplant Patient Distress","Inclusion Criteria:\n\n* Autologous and Allogeneic patients admitted to E1 for planned HSCT\n* Patients with hematologic malignancies requiring HSCT\n* No allergies to lavender or peppermint essential oils\n* Must have received chemotherapy during preparative regimen (single or multi-agent regimen)\n* Adult patient over 18 years of age\n* Able to speak, read, and comprehend English\n* Willing and capable of providing informed consent\n\nExclusion Criteria:\n\n* Patients admitted for Chimeric Antigen Receptor T cell (CART) infusion\n* Patients receiving a transplant for a germ cell tumor diagnosis\n* Unexpected\u002Funplanned admission (e.g., neutropenic fever, confusion, clinical deterioration)\n* Immune effector cell-associated neurotoxicity syndrome (ICANS) grade 1 through 4\n* History of scleroderma\n* History of atrial fibrillation\n* Known history of G6PD deficiency\n* Allergic to lavender or peppermint essential oils\n* Pediatric patient 18 years of age or less\n* Unable to speak, read, and comprehend English\n* Unwilling or incapable of providing informed consent",{"count":20,"type":21},[24],"This randomized controlled trial will evaluate the feasibility and acceptability of an inhaled aromatherapy stick for patients during the acute inpatient phase after hematopoietic cell transplantation (HCT) . The study will also explore whether aromatherapy use is associated with short-term changes in patient-reported cancer-related distress and coping self-efficacy.",[607,608,609,610],"Cancer Distress","Cancer Coping","Hematopoetic Stem Cell Transplant","Aromatherapy",{"date":478,"type":32},{"date":613,"type":32},"2025-06-16",{"date":117,"type":21},{"name":38,"class":39},{"id":617,"slug":618,"hasResults":12,"nctId":619,"briefTitle":620,"officialTitle":621,"acronym":4,"eligibilityCriteria":622,"healthyVolunteers":12,"sex":17,"minAge":623,"maxAge":70,"enrollmentInfo":624,"targetDuration":4,"studyType":22,"phases":626,"briefSummary":627,"conditions":628,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":629,"startDateStruct":630,"completionDateStruct":632,"leadSponsor":633,"locationsCount":40},"100453717","phase-1-niclosamide-in-pediatric-patients-with-relapsed-and-refractory-aml-100453717","NCT05188170","Niclosamide in Pediatric Patients With Relapsed and Refractory AML","Phase 1 Study of Niclosamide (ANA001) in Pediatric Patients With Relapsed and Refractory AML","Inclusion Criteria:\n\n1\\. Prior morphologically-confirmed diagnosis of AML based on WHO Criteria 2. Has previously failed all available and suitable therapies for AML. Disease relapse or the presence of refractory disease after ≥ 2 cycles of intensive chemotherapy; or ≥ 4 cycles of non-intensive chemotherapy or hypomethylating agents (HMAs) must be documented by bone marrow (BM) examination demonstrating ≥ 5% blasts in the BM by morphology or ≥ 1% blasts by flow cytometry,\n\n* 5% blasts in the peripheral blood (confirmed by flow cytometry, cytogenetics or FISH), ≥ 1% MRD\n\n  \\+ by flow cytometry, FISH, PCR or NGS, and not attributable to another cause (EXCEPTION: subjects with frank disease progression in the face of treatment with HMA with or without venetoclax will be considered eligible regardless of treatment cycles administered if they meet the other eligibility criteria). No prior treatment with niclosamide. 3. Age ≥ 2 and ≤ 30 years 4. Body surface area (BSA) ≤ 2.10 m2\n\n  , calculated per the Mostellar formula 5. Must be able to tolerate po or ng medications. 6. Performance status: Subject ≤ 16 years old: Lansky ≥ 50 Subject \\> 16 years old: Karnofsky ≥ 50% 7. Life expectancy of greater than 4 weeks 8. Platelets ≥ 10,000\u002Fmm3 (for subjects with platelets \\\u003C 10,000\u002Fmm3 at baseline, platelet transfusion support is allowed) 9. Measured or calculated creatinine clearance\n* 60 mL\u002Fmin\u002F1.73 m2 (by the Cockcroft-Gault method) within 14 days prior to treatment initiation 10. Total bilirubin ≤ 2.0 x institutional upper limit of normal (ULN) within 14 days prior to treatment initiation (EXCEPTION: Subjects with Gilbert's syndrome may be included if the total bilirubin is\n\n  * 3.0 x ULN) 11. SGOT (AST) ≤ 3.0 x ULN and SGPT (ALT)\n  * 3.0 x ULN within 14 days prior to treatment initiation 12. Patients must have received their last dose of anti-cancer therapy (chemotherapy, immunotherapy, targeted agents, radiotherapy or investigational therapy) at least 2 weeks or 3 half-lives prior to the start of study treatment, whichever is longer. 13. For patients who have received prior hematopoietic stem cell transplants (HSCT), no evidence of GvHD and must be \\> 60 days since the HSCT. HSCT recipients must have completed their last course of tacrolimus, cyclosporine, or mycophenolate \\> 4 weeks before initiation of niclosamide 14. Females of reproductive potential (WOCBP) must have a negative pregnancy test within 14 days prior to study treatment. WOCBP must agree to use adequate contraception (eg, hormonal or barrier methods of birth control; abstinence; sterilized partner) from date of consent through the treatment period, and for 30 days after completion of niclosamide administration 15. Men only: Men must agree to use adequate contraception (eg, hormonal or barrier methods of birth control; abstinence; sterilized partner) from date of consent through the treatment period, and for 30 days after completion of niclosamide administration 16. Ability to understand the purpose and risks of the study and the willingness to sign a written informed consent document containing an authorization to use protected health information (in accordance with national and local subject privacy regulations\n\nExclusion Criteria:\n\n1. Received anticancer therapy (chemotherapy, immunotherapy, radiotherapy, or investigational therapy) within 2 weeks prior to starting study treatment. Administration of hydroxyurea 10 to 20 mg\u002Fkg\u002Fday PO (maximum 1000 mg PO BID) to control high WBC \\> 50 x 103\n\n   \u002Fmm3 is permitted at MD discretion (however, hydroxyurea should be stopped at least 24 hours prior to protocol therapy start).\n2. Receiving any other investigational agents, including niclosamide.\n3. Unresolved toxicities due to prior anticancer therapy, defined as not having resolved to Grade 0 or 1 (by CTCAE version 5 criteria), unless otherwise defined in the inclusion\u002Fexclusion criteria with the exception of alopecia\n4. Acute promyelocytic leukemia (French-American-British Class M3-AML)\n5. Known active central nervous system (CNS) leukemia; subjects can enroll on study if CNS disease can be cleared with intrathecal chemotherapy, in the judgement of the treating physician\n6. Known congenital bleeding disorders, including but not limited to hemophilia\n7. Known active uncontrolled systemic infection\n8. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, uncontrolled symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction, at the time of study entry\n9. Inability to receive administration of niclosamide in the available formulation(s)\n10. Uncontrolled intercurrent illness including, but not limited to, uncontrolled active infection, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n11. Lactating or pregnant female\n12. Known active hepatitis C","2 Years",{"count":625,"type":21},16,[402],"Protocol is designed to evaluate a niclosamide dose escalation scale in combination with cytarabine as a therapeutic modality for pediatric subjects with relapsed\u002Frefractory acute myeloid leukemia.",[407],{"date":478,"type":32},{"date":631,"type":32},"2022-11-21",{"date":117,"type":21},{"name":38,"class":39},""]